Global healthcare firm Novo Nordisk has unveiled plans to build a new insulin filling facility in Denmark, which will involve an investment of around DKK2.1bn ($30.6m).
The new facility is being developed to produce medicines for the treatment of diabetes and obesity.
The 10,300m2 facility will be constructed at the company’s site in Hillerød, and is expected to commence operations in 2019.
Novo Nordisk’s new facility will create around 450 new production and engineering jobs, while the firm already employs around 1,900 people at the site.
Featuring modern insulin production technology, the new facility will increase the production capacity for existing and future products within diabetes.
Novo Nordisk executive vice-president and product supply head Henrik Wulff said: "The investment in Hillerød underscores our long-term ambition to create and maintain jobs in Denmark.
"This year alone we have created 1,000 new jobs in Denmark, of which 500 are in production, primarily in Kalundborg and Hillerød."
Founded in 1992, Hillerød site includes an area of about 1,650,000m2, of which 90,000m2 is used for production, research and development (R&D).
The site features a facility for device R&D and three production facilities, of which one is for moulding and pre-assembly of components, the second one is for filling, assembly and packaging of diabetes finished products and the third is for the production of active pharmaceutical ingredients for haemophilia products.
The company produces prefilled insulin delivery systems such as FlexTouch and FlexPen, as well as needles such as NovoFine and NovoFine Plus.